

Bard1 Life Sciences Ltd

16:19 18 May 2018

BARD1 Life Sciences signs agreement to develop custom research assay

BARD1 Life Sciences Limited (ASX:BD1) has entered into an assay development agreement with Thermo Fisher Scientific for custom research assay development of a multiplex autoantibody test system.

The scope of work includes the transfer of the current BARD1 assay design to Thermo Fisher for optimisation of an autoantibody assay using Thermo Fisher's ProcartaPlex® Technology for BARD1's research use.

The first application of the ProcartaPlex® Technology is to the BARD1-Ovarian test that BARD1 plans to develop for detection of ovarian cancer.

The custom research assay development project will commence this month and is expected to take about nine months.

Evaluating the accuracy of the BARD1-Ovarian test

If the development project is successful, BARD1 and Thermo Fisher will then discuss the potential for Thermo Fisher to supply research autoantibody kits to BARD1 for its use in research studies.

BARD1 chief executive officer Dr Leearne Hinch said: "We are pleased to work with such an experienced partner.

"The development of a RUO BARD1 autoantibody assay for use on Luminex® instrumentation will be an important milestone for the company, enabling us to initiate clinical testing to evaluate the accuracy of the new multiplex BARD1-Ovarian test for early detection of ovarian cancer in early 2019."

READ: BARD1 Life Sciences secures Israeli patent for unique lung cancer test

BARD1 was recently issued a patent in Israel for detecting BARD1 isoforms (proteins) in lung and colorectal cancer.

The company's proprietary technology platform, BARD1, is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers.

BARD1's patent portfolio comprises five patent families with multiple granted and pending patents across key markets including the US, Europe and Japan.


Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

Price: A\$0.03

Market Cap: A\$41.02M

1 Year Share Price Graph



Share Information

Code: BD1

Listing: ASX

52 week High Low
A\$0.07 A\$0.01

Sector: Pharma & Biotech

Website: www.bard1.com

Company Synopsis:

Bard1 Life Sciences Ltd (ASX:BD1) is listed on the Australian Securities Exchange.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.